Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.
Marinda MeertensEline L GiraudMaud B A van der KleijKim WesterdijkNiels A D GuchelaarRoos F BleckmanAmy RiebornAlex L T ImholzHans-Martin OttenAnnelie VulinkMaartje LosPaul HambergWinette T A van der GraafHans GelderblomDirk Jan A R MoesK Esther BroekmanDaan J TouwStijn L W KoolenRon H J MathijssenAlwin D R HuitemaNielka P van ErpIngrid M E DesarNeeltje Steeghsnull nullPublished in: Clinical pharmacokinetics (2024)
TDM reduced the proportion of patients with subtherapeutic exposure levels by ~ 50%. Nonetheless, the added value of TDM for achieving target trough levels of ≥ 20.5 mg/L for pazopanib on survival outcomes could not be confirmed in STS patients.